AstraZeneca's Novel TROP2 Biomarker Predicted Outcomes in Lung Cancer
AstraZeneca's new computational pathology method identified a TROP2 biomarker that predicted improved clinical outcomes with datopotamab deruxtecan in patients with advanced non-small cell lung cancer.
Pharmaceutical company AstraZeneca has released new findings from its TROPION-Lung01 Phase III trial, indicating that a novel TROP2 biomarker, measured using a proprietary computational pathology platform, predicted treatment response in patients with advanced or metastatic non-small cell lung cancer (NSCLC).
The analysis showed that patients treated with datopotamab deruxtecan (Dato-DXd) who had TROP2-QCS biomarker-positive tumors experienced a significantly greater progression-free survival (PFS) benefit compared to those without the biomarker, when compared against docetaxel treatment.
AstraZeneca is collaborating with Roche Tissue Diagnostics to develop a companion diagnostic test for the TROP2-QCS biomarker. The goal is to identify patients most likely to benefit from the therapy. TROP2 is a protein broadly expressed on NSCLC tumor cells, but its predictive value has been unclear with conventional methods.
The computational pathology platform allows for precise quantification of TROP2 within tumor tissue samples. This more accurate measurement could help identify the patient group most likely to benefit from datopotamab deruxtecan, potentially improving treatment selection and patient outcomes.